The role of Globo H and SSEA-4 in the Development and Progression of Cancer, and their Potential as Therapeutic Targets

References

• Khan KK , ShiB, TianYet al. Glycan regulation in cancer, nervous and immune system: a narrative review. Biomed. Res. Ther.6(4), 3113–3120 (2019).
   Web of Science ®Google Scholar
• Reily C , StewartTJ, RenfrowMB, NovakJ. Glycosylation in health and disease. Nat. Rev. Nephrol.15(6), 346–366 (2019).
   PubMed Web of Science ®Google Scholar
• Hakomori SI . Structure and function of glycosphingolipids and sphingolipids: recollections and future trends. Biochim. Biophys. Acta1780(3), 325–346 (2008).
   PubMed Web of Science ®Google Scholar
• Yu AL , HungJT, HoMY, YuJ. Alterations of glycosphingolipids in embryonic stem cell differentiation and development of glycan-targeting cancer immunotherapy. Stem Cells Dev.25(20), 1532–1548 (2016).
   PubMed Web of Science ®Google Scholar
• Varki A , KornfeldS. Historical background and overview. In: VarkiA, CummingsRD, EskoJDet al.(Eds). Essentials of Glycobiology.Cold Spring, NY, USA, 1–18 (2015).
   Google Scholar
• Smith BAH , BertozziCR. The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans. Nat. Rev. Drug Discov.20(3), 217–243 (2021).
   PubMed Web of Science ®Google Scholar
• Laine RA . A calculation of all possible oligosaccharide isomers both branched and linear yields 1.05 × 10.12) structures for a reducing hexasaccharide: the Isomer Barrier to development of single-method saccharide sequencing or synthesis systems. Glycobiology4(6), 759–767 (1994).
   PubMed Web of Science ®Google Scholar
• Kolter T , ProiaRL, SandhoffK. Combinatorial ganglioside biosynthesis. J. Biol. Chem.277(29), 25859–25862 (2002).
   PubMed Web of Science ®Google Scholar
• Varki A , KornfeldS. Biological functions of glycans. In: VarkiA, CummingsRD, EskoJDet al.(Eds). Essentials of Glycobiology.Cold Spring, NY, USA, 77–88 (2015).
   Google Scholar
• Zhang T , de WaardAA, WuhrerM, SpaapenRM. The role of glycosphingolipids in immune cell functions. Front. Immunol.10, 90 (2019).
   PubMedGoogle Scholar
• Klenk E . Über die ganglioside, eine neue Gruppe von zuckerhaltigen Gehirnlipoiden. Z Physiol. Chem.273, 76 (1942).
   Google Scholar
• D'Angelo G , CapassoS, SticcoL, RussoD. Glycosphingolipids: synthesis and functions. FEBS J.280(24), 6338–6353 (2013).
   PubMed Web of Science ®Google Scholar
• Kolter T . Ganglioside biochemistry. ISRN Biochem.2012, 506160 (2012).
   PubMedGoogle Scholar
• Schnaar RL , KinoshitaT. Glycosphingolipids. In: VarkiA, CummingsRD, EskoJDet al.(Eds). Essentials of Glycobiology.Cold Spring, NY, USA, 125–135 (2015).
   Google Scholar
• Patel DS , ParkS, WuELet al. Influence of ganglioside GM1 concentration on lipid clustering and membrane properties and curvature. Biophys. J.111(9), 1987–1999 (2016).
   PubMed Web of Science ®Google Scholar
• Handa K , HakomoriSI. Changes of glycoconjugate expression profiles during early development. Glycoconj. J.34(6), 693–699 (2017).
   PubMed Web of Science ®Google Scholar
• Yamashita T , WadaR, SasakiTet al. A vital role for glycosphingolipid synthesis during development and differentiation. Proc. Natl Acad. Sci. USA96(16), 9142–9147 (1999).
   PubMed Web of Science ®Google Scholar
• Liang YJ , KuoHH, LinCHet al. Switching of the core structures of glycosphingolipids from globo- and lacto- to ganglio-series upon human embryonic stem cell differentiation. Proc. Natl Acad. Sci. USA107(52), 22564–22569 (2010).
   PubMed Web of Science ®Google Scholar
• Yu J , HungJT, WangSHet al. Targeting glycosphingolipids for cancer immunotherapy. FEBS Lett.594(22), 3602–3618 (2020).
   PubMed Web of Science ®Google Scholar
• Zhou D , LeverySB, HsuFFet al. Immunologic mapping of glycomes: implications for cancer diagnosis and therapy. Front. Biosci. (Schol Ed).3, 1520–1532 (2011).
   PubMedGoogle Scholar
• Kailemia MJ , ParkD, LebrillaCB. Glycans and glycoproteins as specific biomarkers for cancer. Anal. Bioanal. Chem.409(2), 395–410 (2017).
   PubMed Web of Science ®Google Scholar
• Wang M , ZhuJ, LubmanDM, GaoC. Aberrant glycosylation and cancer biomarker discovery: a promising and thorny journey. Clin. Chem. Lab. Med.57(4), 407–416 (2019).
   PubMed Web of Science ®Google Scholar
• Aiello NM , StangerBZ. Echoes of the embryo: using the developmental biology toolkit to study cancer. Dis. Model Mech.9(2), 105–114 (2016).
   PubMed Web of Science ®Google Scholar
• Ngamukote S , YanagisawaM, ArigaTet al. Developmental changes of glycosphingolipids and expression of glycogenes in mouse brains. J. Neurochem.103(6), 2327–2341 (2007).
   PubMed Web of Science ®Google Scholar
• Breimer ME , SaljoK, BaroneA, TenebergS. Glycosphingolipids of human embryonic stem cells. Glycoconj. J.34(6), 713–723 (2017).
   PubMed Web of Science ®Google Scholar
• Kannagi R , CochranNA, IshigamiFet al. Stage-specific embryonic antigens (SSEA-3 and -4) are epitopes of a unique globo-series ganglioside isolated from human teratocarcinoma cells. EMBO J.2(12), 2355–2361 (1983).
   PubMed Web of Science ®Google Scholar
• Russo D , CapolupoL, LoombaJSet al. Glycosphingolipid metabolism in cell fate specification. J. Cell Sci.131(24), jcs219204 (2018).
   PubMed Web of Science ®Google Scholar
• Cagnoni AJ , PerezSaez JM, RabinovichGA, MarinoKV. Turning-off signaling by siglecs, selectins, and galectins: chemical inhibition of glycan-dependent interactions in cancer. Front Oncol.6, 109 (2016).
   PubMed Web of Science ®Google Scholar
• Scott DA , DrakeRR. Glycosylation and its implications in breast cancer. Expert Rev. Proteomics.16(8), 665–680 (2019).
   PubMed Web of Science ®Google Scholar
• Bull C , BoltjeTJ, BalnegerNet al. Sialic acid blockade suppresses tumor growth by enhancing T-cell-mediated tumor immunity. Cancer Res.78(13), 3574–3588 (2018).
   PubMed Web of Science ®Google Scholar
• Kölbl AC , AndergassenU, JeschkeU. The role of glycosylation in breast cancer metastasis and cancer control. Front. Oncol.5, 219 (2015).
   PubMed Web of Science ®Google Scholar
• Cumin C , HuangYL, Everest-DassA, JacobF. Deciphering the importance of glycosphingolipids on cellular and molecular mechanisms associated with epithelial-to-mesenchymal transition in cancer. Biomolecules11(1), 62 (2021).
   PubMed Web of Science ®Google Scholar
• De Bousser E , MeurisL, CallewaertN, FestjensN. Human T cell glycosylation and implications on immune therapy for cancer. Hum. Vaccin. Immunother.16(10), 2374–2388 (2020).
   PubMed Web of Science ®Google Scholar
• Yamakawa T , YokoyamaS, KisoN. Structure of main globoside of human erythrocytes. J. Biochem.52, 228–229 (1962).
   PubMed Web of Science ®Google Scholar
• Shevinsky LH , KnowlesBB, DamjanovI, SolterD. Monoclonal antibody to murine embryos defines a stage-specific embryonic antigen expressed on mouse embryos and human teratocarcinoma cells. Cell30(3), 697–705 (1982).
   PubMed Web of Science ®Google Scholar
• Chuang PK , HsiaoM, HsuTLet al. Signaling pathway of globo-series glycosphingolipids and beta1,3-galactosyltransferase V (beta3GalT5) in breast cancer. Proc. Natl Acad. Sci. USA116(9), 3518–3523 (2019).
   PubMed Web of Science ®Google Scholar
• Chang WW , LeeCH, LeePet al. Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis. Proc. Natl Acad. Sci. USA105(33), 11667–11672 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang S , Cordon-CardoC, ZhangHSet al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int. J. Cancer73(1), 42–49 (1997).
   PubMed Web of Science ®Google Scholar
• Cheng JY , WangSH, LinJet al. Globo-H ceramide shed from cancer cells triggers translin-associated factor X-dependent angiogenesis. Cancer Res.74(23), 6856–6866 (2014).
   PubMed Web of Science ®Google Scholar
• Lou YW , WangPY, YehSCet al. Stage-specific embryonic antigen-4 as a potential therapeutic target in glioblastoma multiforme and other cancers. Proc. Natl Acad. Sci. USA.111(7), 2482–2487 (2014).
   PubMed Web of Science ®Google Scholar
• Chen IJ , YangMC, ChenYJ. The prevalence of globo H in different cancer types: breast, pancreatic, lung, gastric, colorectal, liver, and esophageal. Poster presented at: American Association for Cancer Research (AACR) Virtual Annual Meeting (June 22–24, 2020).
   Google Scholar
• Birkle S , ZengG, GaoLet al. Role of tumor-associated gangliosides in cancer progression. Biochimie.85(3–4), 455–463 (2003).
   PubMed Web of Science ®Google Scholar
• Kuo T , TsaiC, LeeC, LaiJ. The role of Globo H in cancer cell survival. Cancer Res.80, 2934 (2020).
   Google Scholar
• Rigiracciolo DC , SantollaMF, LappanoRet al. Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells. J. Exp. Clin. Cancer Res.38(1), 58 (2019).
   PubMedGoogle Scholar
• Sulzmaier FJ , JeanC, SchlaepferDD. FAK in cancer: Mechanistic findings and clinical applications. Nat. Rev. Cancer14(9), 598–610 (2014).
   PubMed Web of Science ®Google Scholar
• Liu YY , GuptaV, PatwardhanGAet al. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. Mol. Cancer9, 145 (2010).
   PubMed Web of Science ®Google Scholar
• Biswas S , BiswasK, RichmondAet al. Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction. J. Immunol.183(8), 5050–5058 (2009).
   PubMed Web of Science ®Google Scholar
• Peguet-Navarro J , SportouchM, PopaIet al. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J. Immunol.170(7), 3488–3494 (2003).
   PubMed Web of Science ®Google Scholar
• Tsai Y , HuangJ, ChengJet al. A prevalent cancer associated glycan, globo H ceramide, induces immunosuppression by reducing Notch1 signaling. J. Cancer Sci Ther.5(7), 264–270 (2013).
   Google Scholar
• Cheng J , WangS, HungJet al. Globo-H ceramide induceds T cell immunosuppression via A2A receptor (A2A-R) and cAMP/PKA pathway. Eur. J. Immunol.46(Suppl. 1), 705–706 (2016).
   Google Scholar
• Jiang X , WangJ, DengXet al. The role of microenvironment in tumor angiogenesis. J. Exp. Clin. Cancer Res.39(1), 204 (2020).
   PubMed Web of Science ®Google Scholar
• Gullino PM . Prostaglandins and gangliosides of tumor microenvironment: their role in angiogenesis. Acta Oncol.34(3), 439–441 (1995).
   PubMed Web of Science ®Google Scholar
• Munaron L . Intracellular calcium, endothelial cells and angiogenesis. Recent Pat. Anticancer Drug Discov.1(1), 105–119 (2006).
   PubMed Web of Science ®Google Scholar
• Eller CH , YangG, OuerfelliO, RainesRT. Affinity of monoclonal antibodies for Globo-series glycans. Carbohydr. Res.397, 1–6 (2014).
   PubMed Web of Science ®Google Scholar
• Huang YL , HungJT, CheungSKet al. Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer. Proc. Natl Acad. Sci. USA110(7), 2517–2522 (2013).
   PubMed Web of Science ®Google Scholar
• Ye F , LiY, HuYet al. Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma. Int J. Gynecol Cancer.20(6), 958–964 (2010).
   PubMed Web of Science ®Google Scholar
• Nakamura Y , MiyataY, MatsuoTet al. Stage-specific embryonic antigen-4 is a histological marker reflecting the malignant behavior of prostate cancer. Glycoconj. J.36(5), 409–418 (2019).
   PubMed Web of Science ®Google Scholar
• Gottschling S , JensenK, WarthAet al. Stage-specific embryonic antigen-4 is expressed in basaloid lung cancer and associated with poor prognosis. Eur. Respir. J.41(1), 656–663 (2013).
   PubMedGoogle Scholar
• Brimble SN , SherrerES, UhlEWet al. The cell surface glycosphingolipids SSEA-3 and SSEA-4 are not essential for human ESC pluripotency. Stem Cells25(1), 54–62 (2007).
   PubMed Web of Science ®Google Scholar
• Sivasubramaniyan K , HarichandanA, SchilbachKet al. Expression of stage-specific embryonic antigen-4 (SSEA-4) defines spontaneous loss of epithelial phenotype in human solid tumor cells. Glycobiology25(8), 902–917 (2015).
   PubMed Web of Science ®Google Scholar
• Bossennec M , DiRoio A, CauxC, Menetrier-CauxC. MDR1 in immunity: Friend or foe?Oncoimmunology7(12), e1499388 (2018).
   PubMed Web of Science ®Google Scholar
• Aloia A , PetrovaE, TomiukSet al. The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features. Breast Cancer Res.17(1), 146 (2015).
   PubMedGoogle Scholar
• Yuno T , MiyataY, MatsuoTet al. Relationship between stage-specific embryonic antigen-4 and anti-cancer effects of neoadjuvant hormonal therapy in prostate cancer. Anticancer Res.40(10), 5567–5575 (2020).
   PubMed Web of Science ®Google Scholar
• Hung TC , LinCW, HsuTLet al. Investigation of SSEA-4 binding protein in breast cancer cells. J. Am. Chem. Soc.135(16), 5934–5937 (2013).
   PubMed Web of Science ®Google Scholar
• Fraschilla I , PillaiS. Viewing Siglecs through the lens of tumor immunology. Immunol. Rev.276(1), 178–191 (2017).
   PubMed Web of Science ®Google Scholar
• Stanczak MA , SiddiquiSS, TrefnyMPet al. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J. Clin. Invest.128(11), 4912–4923 (2018).
   PubMed Web of Science ®Google Scholar
• Ghazarian H , IdoniB, OppenheimerSB. A glycobiology review: Carbohydrates, lectins and implications in cancer therapeutics. Acta Histochem.113(3), 236–247 (2011).
   PubMed Web of Science ®Google Scholar
• Vasta GR , AmzelLM, BianchetMAet al. F-type lectins: A highly diversified family of fucose-binding proteins with a unique sequence motif and structural fold, involved in self/non-self-recognition. Front. Immunol.8, 1648 (2017).
   PubMed Web of Science ®Google Scholar
• Bornhofft KF , GoldammerT, ReblA, GaluskaSP. Siglecs: A journey through the evolution of sialic acid-binding immunoglobulin-type lectins. Dev. Comp. Immunol.86, 219–231 (2018).
   PubMed Web of Science ®Google Scholar
• Linenberger ML . CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia19(2), 176–182 (2005).
   PubMed Web of Science ®Google Scholar
• Takamiya R , OhtsuboK, TakamatsuSet al. The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-beta secretion from monocytes/macrophages through the DAP12-Syk pathway. Glycobiology23(2), 178–187 (2013).
   PubMed Web of Science ®Google Scholar
• Mitra N , BandaK, AltheideTKet al. SIGLEC12, a human-specific segregating (pseudo)gene, encodes a signaling molecule expressed in prostate carcinomas. J. Biol. Chem.286(26), 23003–23011 (2011).
   PubMed Web of Science ®Google Scholar
• Jandus C , BoliganKF, ChijiokeOet al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J. Clin. Invest.124(4), 1810–1820 (2014).
   PubMed Web of Science ®Google Scholar
• Farkona S , DiamandisEP, BlasutigIM. Cancer immunotherapy: the beginning of the end of cancer?BMC Med.14, 73 (2016).
   PubMed Web of Science ®Google Scholar
• Oiseth SJ , AzizMS. Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead. J. Cancer Metastasis Treat.3, 250–261 (2017).
   Google Scholar
• Klemm F , JoyceJA. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol.25(4), 198–213 (2015).
   PubMed Web of Science ®Google Scholar
• Swartz MA , IidaN, RobertsEWet al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res.72(10), 2473–2480 (2012).
   PubMed Web of Science ®Google Scholar
• Rossig C , KailayangiriS, JamitzkyS, AltvaterB. Carbohydrate targets for CAR T cells in solid childhood cancers. Front. Oncol.8, 513 (2018).
   PubMed Web of Science ®Google Scholar
• Alam S , FedierA, KohlerRS, JacobF. Glucosylceramide synthase inhibitors differentially affect expression of glycosphingolipids. Glycobiology25(4), 351–356 (2015).
   PubMed Web of Science ®Google Scholar
• Walter RB . Brief overview of antibody–drug conjugate therapy for acute leukemia. Expert Opin. Biol. Ther.21, 795–799 (2020).
   PubMed Web of Science ®Google Scholar
• Gutierrez M , HamidO, ShumEet al. Trial in progress: a Phase I/II, open-label, dose-escalation, safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors. J. Clin. Oncol.18(Suppl. 15), [ abstract TPS3166] (2020).
   Google Scholar
• No authors listed . Siglec-15: an attractive immunotherapy target. Cancer Discov.10(1), 7–8 (2020).
   Web of Science ®Google Scholar
• OBI Pharma . OBI-888 completes phase I safety evluation and demonstrates its saefty and tolerability with no major concerns. Investor announcement (2019). www.obipharma.com/en/investor-announcements/obi-888-completes-phase-i-safety-evaluation-and-demonstrates-its-safety-and-tolerability-with-no-major-concerns/
   Google Scholar
• Tsimberidou AM , AjaniJA, HsuPet al. A Phase I/II, open-label, dose-escalation, and cohort-expansion study evaluating the safety, pharmacokinetics, and therapeutic activity of OBI-999 in patients with advanced solid tumors. J. Clin. Oncol.38(Suppl. 15), [ abstract TPS3657] (2020).
   Web of Science ®Google Scholar
• Yang MC , ShiaCS, LiWFet al. Preclinical studies of OBI-999: a novel Globo H-targeting antibody–drug conjugate. Mol Cancer Ther.20(6), 1121–1132 (2021).
   PubMed Web of Science ®Google Scholar
• Ruggiero FM , Rodriguez-WalkerM, DaniottiJL. Exploiting the internalization feature of an antibody against the glycosphingolipid SSEA-4 to deliver immunotoxins in breast cancer cells. Immunol. Cell Biol.98(3), 187–202 (2020).
   PubMed Web of Science ®Google Scholar
• Soliman C , ChuaJX, VankemmelbekeMet al. The terminal sialic acid of stage-specific embryonic antigen-4 has a crucial role in binding to a cancer-targeting antibody. J. Biol. Chem.295(4), 1009–1020 (2020).
   PubMed Web of Science ®Google Scholar
• Pfeifer R , LockD, AloiaAet al. Sialyl glycolipid stage-specific embryonic antigen 4 (SSEA4) - A novel target for CAR T cell therapy of solid cancers. Mol. Ther.24(Suppl. 1), 259 (2016).
   Google Scholar
• Dees S , GanesanR, SinghS, GrewalIS. Emerging CAR-T cell therapy for the treatment of triple-negative breast cancer. Mol. Cancer Ther.19(12), 2409–2421 (2020).
   PubMed Web of Science ®Google Scholar
• OBI Pharma . OBI Pharma updates on clinical trial activities during Covid-19 pandemic (2020). www.obipharma.com/en/news/obi-pharma-updates-on-clinical-trial-activities-during-covid-19-pandemic/
   Google Scholar
• Adobati E , PanzaL, RussoGet al. In vitro mimicry of CaMBr1 tumor-associated antigen by synthetic oligosaccharides. Glycobiology.7(2), 173–178 (1997).
   PubMed Web of Science ®Google Scholar
• Astronomo RD , BurtonDR. Carbohydrate vaccines: developing sweet solutions to sticky situations?Nat. Rev. Drug Discov.9(4), 308–324 (2010).
   PubMed Web of Science ®Google Scholar
• Jin KT , LanHR, ChenXYet al. Recent advances in carbohydrate-based cancer vaccines. Biotechnol. Lett.41(6–7), 641–650 (2019).
   PubMed Web of Science ®Google Scholar
• Kensil CR , PatelU, LennickM, MarcianiD. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol.146(2), 431–437 (1991).
   PubMed Web of Science ®Google Scholar
• Slovin SF , RagupathiG, AdluriSet al. Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc. Natl Acad. Sci. USA96(10), 5710–5715 (1999).
   PubMed Web of Science ®Google Scholar
• Gilewski T , RagupathiG, BhutaSet al. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a Phase I trial. Proc. Natl Acad. Sci. USA98(6), 3270–3275 (2001).
   PubMed Web of Science ®Google Scholar
• Danishefsky SJ , ShueYK, ChangMN, WongCH. Development of Globo-H cancer vaccine. Acc Chem. Res.48(3), 643–652 (2015).
   PubMed Web of Science ®Google Scholar
• Huang CS , YuAL, TsengLMet al. Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: Phase II randomized, placebo-controlled study. J. Immunother. Cancer8(2), (2020).
   Web of Science ®Google Scholar
• Rugo HS , ChowLWC, CortesJet al. Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence. Cancer Res.80(Suppl. 4), [ abstract OT1-08-03] (2020).
   Web of Science ®Google Scholar
• Rugo HS , CortesJ, ChowLWCet al. The GLORIA study: A Phase III, randomized, open-label study of the anti-Globo H vaccine adagloxad simolenin (OBI-822)/OBI-821 in the adjuvant treatment of patients with high-risk, early-stage, Globo H-positive, triple-negative breast cancer. Presented at the San Antonio Breast Cancer Symposium, Virtual Symposium (December 8–11, 2020). http://graspcancer.org/wp-content/uploads/2020/12/Group-16-Rugo.pdf
   Google Scholar
• Li CW , LimSO, ChungEMet al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell.33(2), 187–201 (2018).
   PubMed Web of Science ®Google Scholar
• Goossens N , NakagawaS, SunX, HoshidaY. Cancer biomarker discovery and validation. Transl Cancer Res.4(3), 256–269 (2015).
   PubMed Web of Science ®Google Scholar
• O'Cearbhaill RE , RagupathiG, ZhuJet al. A Phase I study of unimolecular pentavalent (Globo-H-GM2-sTn-TF-Tn) immunization of patients with rpithelial ovarian, fallopian tube, or peritoneal cancer in first remission. Cancers (Basel).8(4), (2016).
   PubMed Web of Science ®Google Scholar
• O'Cearbhaill RE , TasonosA, ZhouQet al. Polyvalent vaccine-KLH conjugate and OPT-821 with bevacizumab (BEV) in patients with ovarian cancer in second or greater remission. J. Clin. Oncol.31(Suppl. 15), 5550 (2013).
   Web of Science ®Google Scholar
• Shiah HS , StruassJF, LinCCet al. OBI-833 was safe and immunogenic, without treatment-related SAEs, in a Phase I dose-escalation trial. Ann. Oncol.31(Suppl. 6), S1270 (2020).
   PubMedGoogle Scholar
• Ho CL , LeeKY, ShiahHSet al. A Phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients. Ann. Oncol.31(Suppl. 6), S1397 (2020).
   PubMedGoogle Scholar